|
Post by rook1405 on Jan 5, 2016 10:27:31 GMT -5
Bradley, I was wondering the exact same thing. The licensing agreement doesn't seem to address such a situation, but then again, that isn't surprising. Anyone care to weigh in?
|
|
|
Post by rvc on Jan 5, 2016 10:29:01 GMT -5
short covering...it'll get worse once institutions sell
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jan 5, 2016 10:38:00 GMT -5
short covering...it'll get worse once institutions sell They had to have been selling the past couple of months. We will know for sure when the data comes out.
|
|
|
Post by rch51 on Jan 5, 2016 10:42:45 GMT -5
if Sanofi was truly sandbagging then whats stopping them from buying a stake in the company today at the best discount possible? Someone could by 25% for 100 million today? we could see 50 million volume today? What's stopping them? An epic lawsuit. There's no way Sanofi gets anywhere near this company.
|
|
|
Post by kball on Jan 5, 2016 10:50:12 GMT -5
if Sanofi was truly sandbagging then whats stopping them from buying a stake in the company today at the best discount possible? Someone could by 25% for 100 million today? we could see 50 million volume today? What's stopping them? An epic lawsuit. There's no way Sanofi gets anywhere near this company. They still might enjoy one.
|
|
|
Post by wmdhunt on Jan 5, 2016 11:05:15 GMT -5
How much will I miss SNY? Stick your finger in a bucket of water and pull it back out. Observe how much SNY will be missed.
|
|
|
Post by biffn on Jan 5, 2016 11:16:01 GMT -5
Wouldn't Teva be the logical choice and line up with the move to TASE? jpg will kill me but I wonder the same for this reason. If Al Mann's goal is to have Afrezza available to type 1 diabetes (type 2), Teva could sell Afrezza for the same cost as subq fast acting. That will get Afrezza on the insurance formularies. From there, patient results and physicians seeing better or equal HgA1c results with happier patients should take afrezza the rest of the way.
Israel would be a perfect market for next approval and further testing.
|
|